TACE联合肿瘤间质注射碘油化疗药物治疗肝癌的临床研究
|
摘要
研究背景
原发性肝癌(HCC)的发生发展是一个多因素、多阶段、多基因变异的复杂过程,与机体的免疫状况密切相关,尤其是与T细胞的细胞免疫有关,但受多种因素的调节,肿瘤患者的机体免疫功能不同程度地发生紊乱。多数学者认为在机体的抗肿瘤免疫中细胞免疫占主导地位,研究表明,T淋巴细胞和NK细胞的比例及功能变化与肿瘤的发展、扩散有明显的相关性。有研究表明HCC患者外周血中CD3,CD4降低,CD8增高,免疫功能低下,恶变细胞所产生的免疫抑制是肿瘤患者免疫功能低下的主要原因。
肿瘤免疫主要与T淋巴细胞的细胞免疫有关,T淋巴细胞亚群是反映机体细胞免疫功能的一个指标。T淋巴细胞是由不同亚群组成的,外周血T细胞亚群在数量上的协调比例,特别是CD4/CD8的比值是反映细胞免疫平衡与否的敏感指标,有助于反映机体免疫反应的调节能力。其中CD4+T淋巴细胞一般认为处于细胞免疫的核心,以其主要分泌细胞因子调节肿瘤免疫被称之为辅助性T淋巴细胞(Th),Th是人类主要组织相溶性抗原(MHC)Ⅱ类分子限制性T细胞,由于大多数肿瘤细胞不表达MHCⅡ类分子,故此类分子不能直接识别肿瘤细胞,而是依赖抗原提呈细胞如B细胞、巨噬细胞提呈相关抗原,对之进行特异性激发后,才分泌淋巴因子(如IL-2、r-干扰素等),激活B细胞、巨噬细胞、NK细胞,并通过其活化的细胞发挥抗肿瘤作用。Ts细胞(suppressor T cell)即抑制性T细胞在宿主免疫机制中起着复杂的抑制调控作用。当发生肿瘤后,Ts在功能和数量上都显著增强,抑制机体对肿瘤的免疫效应,从而使肿瘤逃逸机体的免疫监视,促进了肿瘤的生长。大量体外实验证实,Th和Ts细胞在正常情况下保持着恒定的比值,某一亚群变化可直接影响到群体功能,两者相互制约构成机体重要的免疫调节机制。
肝癌的发生发展也同时与细胞凋亡存在着密切的关系,体外培养的肝癌细胞和体内发生的肝癌细胞均存在着细胞凋亡现象。未经治疗的肝癌会发生自发性癌细胞凋亡,恶性程度越高凋亡指数越大。肝癌时肿瘤细胞的增殖指数与凋亡指数呈正相关,从正常肝脏、癌前病变到肝癌,凋亡率随增殖率增高而增高,但其增高的幅度明显小于细胞增殖增高的幅度。肝癌组织中肿瘤细胞凋亡明显高于正常肝组织及癌周肝组织。细胞凋亡在肿瘤的发生发展中可能具有双面作用：细胞凋亡可能抑制癌细胞生长；也可能通过凋亡筛除那些生命力低下或表型类似正常细胞的肿瘤细胞,而选择侵袭力强增殖旺盛的细胞克隆,促进肿瘤发生发展。所以研究细胞凋亡的机制及凋亡在疾病过程中的作用,不但可以了解肿瘤发生发展的机理,更重要的是从一个全新的角度认识肿瘤细胞的生物学特性,为肿瘤治疗开辟新的途径提供了重要的理论依据。
选择经肝动脉化疗栓塞术(transcatheter arterial chemoembolizaton, TACE)是不能切除肝癌公认的首选治疗方法,经肝动脉化疗栓塞治疗肝癌后,肿瘤细胞被杀死,肿瘤组织出现凝固性坏死,肿瘤细胞负荷减少,使肿瘤释放的TNF减少,免疫抑制因子的产生亦大大减少,减弱了对机体的免疫功能的影响,机体免疫细胞指标有所改善。经手术和栓塞治疗后肝癌患者的免疫功能受抑减轻。但肝动脉化疗栓塞治疗常包括栓塞和化疗两部分,化疗则抑制机体的免疫功能,所以对机体免疫功能的影响颇为复杂。
另一方面,一般认为TACE作用机制是局部化疗和血管栓塞引起了肿瘤组织细胞坏死,但近年来发现栓塞引起的缺血缺氧是肿瘤细胞凋亡强有力的基因诱导动因,缺血数分钟就有即刻早期基因表达,缺氧也可以诱导凋亡基因表达增高,缺血至少可诱导80种以上的基因表达,包括促进细胞凋亡基因表达增高,抑制凋亡基因表达下降,使未凝固坏死的肝癌肿瘤细胞发生凋亡。因此,凋亡在TACE治疗肝癌所引起的肿瘤组织死亡中具有重要的作用,并且有可能是TACE治疗肝癌的其中一重要机制。
但由于肝癌易转移和复发特性,任何单一治疗手段均不满意。选择经肝动脉化疗栓塞术后,但仍有大量病例常存在瘤灶栓塞不充分,TACE时经血管内注入的栓塞剂-碘油化疗药物混合乳剂少,致使瘤灶内碘油化疗药物沉积不充分,无碘油沉积部分病灶则在短期内快速增生,是此类肝癌患者治疗失败和局部复发进展的主要原因。近年,有研究直接将细胞毒药物或生物制剂直接植入肿瘤组织或其周围的间质组织内,对肿瘤细胞进行直接攻击的方法,即经皮穿刺瘤内抗癌药物注射间质治疗(interstitial therapy, IT)。在肿瘤局部缓慢释放,持续保持较高的浓度,杀灭肿瘤细胞,即为缓释化疗(slow-release chemotherapy)。
碘油是一种碘含量37%-39%的脂肪酸乙脂亚麻子油,不透X线,具有X线透视下适时监测其弥散范围的优点,同时能选择性地较长时间滞留在肝肿瘤组织中,不像大多数生物载体那样在体内易被降解或失去活性,也不会因癌细胞突变而失去特异性,可以作为较好的载体进行瘤内药物注射。碘油作为粘稠的油性液体,可以完全包围癌细胞阻碍癌细胞与组织液进行物质交换及氧的获取,使细胞水肿和脂肪变性,重度持续缺氧引发细胞凋亡和死亡。
目前仅有少量文献报道经皮肝穿刺瘤内注入碘油化疗药物乳剂进行肿瘤间质治疗肝癌的临床研究,其中对肝癌患者免疫功能的影响、诱导肿瘤细胞凋亡的基础研究甚少。我们采用TACE联合经皮肝穿刺瘤内注射碘油化疗药物,进行肿瘤间质治疗,一方面探讨该序贯治疗模式的临床疗效及其病理变化,一方面通过流式细胞仪(FCM)检测外周血T淋巴细胞亚群免疫功能的变化,所诱导的肿瘤细胞凋亡变化,初探其对免疫功能的影响、诱导肿瘤细胞凋亡在该治疗模式中的作用,并预期是其重要的治疗机制之一。我们将该治疗模式的临床研究和基础研究结合在一起,这是本研究的特色创新之处,尚未见类似报道。
目的
研究单纯经肝动脉化疗栓塞(transcatheter arterial chemoembolizaton,TACE)联合经皮肝瘤内碘油化疗药物注射肿瘤间质治疗(interstitial therapy, IT)肝癌的临床疗效,病理变化,介入术前后肝癌患者外周血T淋巴细胞亚群及免疫球蛋白的变化及意义。探讨联合肿瘤间质治疗后诱导肝癌肿瘤细胞凋亡的变化及其在肿瘤治疗中的作用机制和意义。
材料与方法
将60例肝癌患者分成两组,对照组(A组)30例行单纯TACE治疗,实验组(B组)30例行TACE联合经皮肝瘤内药物注射碘油化疗药物肿瘤间质治疗。观察患者术后发热等不良反应,术前及术后1周抽取2组患者外周血,常规检测血常规、肝肾功能,观察其变化,术后两月复查和随访,观察2组患者术后一月瘤灶内碘油沉积情况以及术后半年肿瘤局控率,1、2年生存率以及中位生存期。应用流式细胞术检测外周血T淋巴细胞亚群(CD3+T、CD4+T、CDS+T、CD4+T/CD8+T),检测免疫球蛋白和补体C3、C4水平变化,观察免疫功能的改变。术后一月肿瘤穿刺活检取材,病理染色观察病理改变：采用流式细胞仪Annexin-V/PI双染法检测,观察肿瘤细胞凋亡率、死亡率。
结果
A组患者术后体温正常者7例,低度发热者3例、中度发热7例、高度发热13例,B组体温正常16例、低度发热8例、中度发热4例、高度发热2例,χ2检验两组比较有显著性统计学差异,P<0.01。配对t检验显示B组白细胞、血红蛋白术前术后差值明显低于A组,两组比较有显著性统计学差异,P<0.01,B组血小板术前术后差值低于A组,有统计学差异,P<0.05。术后A组白细胞明显高于B组,两组比较有显著性统计学差异,P<0.01；术后A组血小板、血红蛋白要低于术后B组,但两组比较无统计学意义,P>0.05。配对t检验显示B组谷丙转氨酶、谷草转氨酶术前术后差值明显低于A组,两组比较有显著性统计学差异,P<0.01,B组总胆红素指数术前术后差值低于A组,有统计学差异,P<0.05,B组血白蛋白术前术后差值低于A组,但两组间比较无统计学差异,P>0.05。术后A组谷丙转氨酶、谷草转氨酶、总胆红素指数均明显高于B组、血白蛋白明显低于B组,两组比较有显著统计学差异,P<0.05。配对t检验显示B组血尿素氮术前术后差值低于A组,两组比较有统计学差异,P<0.05；B组血肌苷术前术后差值低于A组,但无统计学意义,P>0.05。术后尿素氮、肌苷A组均高于B组,但两组比较无统计学意义,P>0.05。A组手术后碘油沉积率于<50%、50-75%、>75%范围者各为8、12、10例；B组分别为0、12、8例,A、B两组手术后碘油沉积率比较有显著性统计学差异,P<0.05；A组手术后甲胎球蛋白降低率于<50%、>50%范围者各为13、17例,B组分别为5、25例,A、B两组甲胎球蛋白比较有统计学差异,P<0.05(见表5)。A组手术后肿瘤缩小率于<25%、25%-50%、50-75%、>75%者各为23、6、1、0例；B组分别为17、12、1、0,但A、B两组比较无统计学意义,P>0.05。A组手术后6个月复查稳定无复发进展的为12例,复发进展的为18例；B组分别为20、10例,A、B两组手术后6月局控率相比较有统计学差异,P<0.05。A组1,2年生存率80%,43%,中位生存期20.5月。B组1、2年生存率90%,60%,中位生存期22月。外周血T淋巴细胞亚群的结果显示A组单纯经肝动脉化疗栓塞肝癌患者,手术后一周CD3、CD4及CD4/CD8升高,CD8降低,手术前后CD4及CD4/CD8差异有显著性(P<0.05),CD3、及CD8则无统计学差异；B组联合肿瘤间质治疗后,其外周血T淋巴细胞较A组变化更为明显,手术前后CD3、CD4及CD4/CD8升高,CD8降低,手术前后具有非常显著性统计学差异(P<0.01),且A、B两组术后比较,除CD3外统计学亦有显著性差异(P<0.05)。免疫球蛋白和补体检测结果,A组术后免疫球蛋白和补体有所升高,以IgG、IgA、C4升高明显,手术前后有显著性统计学差异,(P<0.05),但IgM、C3手术前后无显著性统计学差异(P>0.05)；B组手术前后仅IgG有所升高,具有显著性统计学差异(P<0.01),IgA、IgM、C3、C4无显著性统计学差异(P>0.05),B组IgG、IgM手术前后差值较A组升高,有显著性统计学差异(P<0.05), IgA、C3、C4无显著性统计学差异(P>0.05)。A组瘤灶病理以大量肿瘤细胞凝固性坏死改变为主,B组则可见大量肿瘤细胞脂肪样变性坏死。A、B两组患者正常肝脏组织流式细胞仪Annexin V/PI双染法凋亡率相比较无统计学意义；两组正常肝脏组织的坏死率比较也无统计学意义；B组患者肿瘤组织凋亡率显著高于A组,两组相比较有统计学差异,P<0.05；A组肿瘤边缘组织死亡率显著高于B组,两组死亡率比较有显著性统计学差异,P<0.01。
结论
TACE联合肿瘤间质注射碘油化疗药物治疗肝癌,可以显著提高瘤灶碘油沉积率,提高肿瘤局控率,降低TACE术后残留瘤灶复发率,延长患者生存期,减轻介入术后不良反应。单纯TACE治疗肝癌增强患者细胞免疫功能,对体液免疫影响较小。联合瘤内碘油化疗药物乳剂注射肿瘤间质治疗的方法可以更大程度改善患者细胞免疫和体液免疫功能。经动脉化疗栓塞诱导大量癌细胞进入凋亡,是TACE联合瘤内药物注射碘油化疗药物肿瘤间质治疗肝癌的重要机制,该治疗模式可以促进肝癌细胞凋亡,对于进一步提高肝癌的疗效具有积极的意义,而其所引致的急性凝固性坏死改变、大量急性肿瘤溶解坏死等不良反应较少,因此是一种相对安全、稳妥、有效、和具有前景的肝癌治疗模式。
Background
The development of primary hepatic carcinoma is a process with multiple factor, multiple stage, polygenic variation, close correlated with immune state, especially T lymphocyte cell. The process is regulated by multiple factor, accompanied with confused immune state to some extent. Majority scholar think that cell mediated immunity occupy the master position in immune. Some research showed the proportion and metergasis of T lymphocyte cells and NK cells are close related with the development and diffusion of tumor. And some research showed that of T lymphocyte subsets in peripheral blood in patients with HCC, CD3 and CD4 degraded, CD8 increased, immune function was weak, that was the major cause of weak immune of which tumor cells resulted in immune suppression.
Tumor immunity is related with T lymphocyte cell mediated immunity in major, which reflect organism immune function. T lymphocyte subsets are consist of different subsets, especially CD4/CD8. It is the sensitive reflection against the balance of cell mediated immunity. CD4+T lymphocyte cells are the core of the cell mediated immunity, which regulate immunoreactive function by excreting cytokine, named helper T lymphocyte. Th is the restriction T lymphocyte of major histocompatibility antigen(MHC)classⅡmolecule. Because most tumor cells do not present MHCⅡ, this kind molecule do not direct identify tumor cells, but rely on antigen presenting cell, such as B lymphocyte, macrophagus to present related antigen and secret lymphokine, interleukin-2, r-interferon, and so on, so that activate B lymphocyte, macrophagus, NK cell to play its effective resisting tumor.
Substantial evidence that has been expressed indicates that the cell apoptosis is related with the development of the tumor, the occurrence of the tumor closely, and hepatoma carcinoma cells cultured in vitro and esoteric all existed phenomenon of apoptosis. Spontaneous malignant cell apoptosis happened to hepatoma untreated, and malignancy to much more extent, higher index of apoptosis. It is positive correlation between proliferation index and apoptotic index in liver cancer. From normal liver to lesion precancerous and hepatoma, apoptosis percentage increased as proliferation increased. It is obviously higher of apoptosis in liver cancer tumor tissue than in the normal liver tissue. There are two sides of apoptois probably, one side restraining growth, another eliminating weak vitality tumor cells so that strong invasiveness tumor cells cloning and developing. So to study the mechanism and effectiveness of apoptosis could supply an important theory basis on new pathway of tumor treatment.
Primary hepatic carcinoma is one of the most common malignant tumors in our country. Any single therapeutic tool is not satisfactory with liver cancer for the characteristic of easy metastasis and recurrence. Transcatheter arterial chemoembolizaton, TACE, is the first of chosen treatment methods, but there are still insufficenicy of embolization in many cases which lipiodol chemotherapeutics emulsion deposited in tumor focus is not enough so that rapid hyperplasy in tumor focus without lipiodol deposited. So it is the major cause of treatment failure and recurrence progression in local tumor region to the patients with liver cancer. There were any investigations implanting cytotoxic drug or biological agents directly into tumor tissue or peripheral interstitial substance recently, that is interstitial therapy, IT, forming the slow-release chemotherapy which killed tumor cells in local tumor region by slow released chemotherapy and sustained high concentrate agents.
Transcatheter arterial chemoembolizaton, TACE, is the first selection to unable removal hepatoma. After TACE, a large amount of tumor cells were killed, coagulation necrosis in tumor appeared and tumor cell burden alleviate, so immune suppression factors, TNF, decreased and weakened its influence to immune function. But Transcatheter arterial chemoembolizaton include chemo and embolization which make influence to organism immune function complex.
Lipiodol is a kind of fatty acid aethyl conjulin with iodine contents about 37%-39%. There is property of lipiodol not penetrated by X-ray, monitoring its diffusion scope at the proper moment through X-ray, being detained long term in tumor tissue, not easy to be missing activity and specificity for tumor cell mutation. So lipiodol is a better carrier adapted to injection into tumor, it can surround tumor cell to hinder material and oxygen exchange, then make cells hydropsia, fatty degeneration and death. But there were only few basic researches about percutaneous chemotherapic agents lipiodol emulsion injection.
On another respect, common standpoint of the mechanism of TACE is that local chemoembolization bring up the tumor cells necrosis. But recently it was found that ischemic and oxygen deficiency were the reason of inducing tumor cells apoptosis, immediate early gene expression for several minutes after ischemic and oxygen deficiency. Ischemic and oxygen deficiency could induce more than 80 gene expression including that expression of gene promoting apoptosis increases and expression of gene restraining apoptosis descend. So apoptosis play an important role in tumor tissue necrosis due to TACE in patients with hepatoma. And it is an important mechanism to TACE probably of the apoptosis induced by TACE.
We combined TACE with percutaneous chemotherapic agents lipiodol emulsion injection to make interstitial therapy in liver cancer, in order to approach the clinic curative effect of this sequential therapy and pathological change in one side, to explore the characteristics and significances in immunology changes of blood subgroups of lymphocyte T, to explore significances and effective of the tumor cell apoptosis induced by the treatment method in another side. We got the clinic research and basic research together, that is special feature, new ideals in our study, and not yet reported.
Objective
To study the clinic curative effect by transcatheter arterial chemoembolizaton combined with interstitial therapy for liver cancer and pathological change first, to explore the characteristics and significances in immunology changes of blood subgroups of lymphocyte T, to explore significances and effective of the tumor cell apoptosis induced by the this sequential therapy secondly.
Methods
60 patients with liver cancer were divided into two groups, A group received transcatheter arterial chemoembolizaton, and B group received transcatheter arterial chemoembolizaton combined with interstitial therapy of percutaneous lipiodol and anti-cancer agents injection intratumorly for liver cancer. Then to observe the percent of lipiodol deposited in the tumor, local control ratio of 6 months, survive rate in 2 years, the median survival time, adverse effect, and puncher biopsy one month postoperative. T lymphocyte cell subsets, CD3+, CD4+,CD8+, CD4+/CD8+ in the peripheral blood before and one week after operation were measured by flow cytometry; immune globulin determined by single radial immunodiffusion. The apoptosis percentage, death percentage of tumor cells was measured by flow cytometry with Annexin V/PI staining.
Results
There was significant difference in the percent of fever between two groups, P< 0.01, normal temperature 7 instances in A group, low fever 3 instance, middle lever 7 instances, high lever 13 instances; normal temperature 16 instances in B group, low fever 8 instance, middle lever 4 instances, high lever 2 instances. There was no significant difference of WBC, HB, PLB preoperative in both A and B groups (P> 0.05).There was significant difference of WBC, HB between preoperative and postoperative in both A and B groups (P<0.05). And significant difference of WBC, HB between A and B group postoperative (P<0.05). It was higher of WBC in A group preoperative than postoperative, there was significant difference, P<0.05, but in B group there was no significant difference, P>0.05. And it was higher of HB in A group preoperative than postoperative, there was significant difference, P<0.05, but in B group there was no significant difference, P>0.05. There was significant difference in the percent of lipiodol deposited in the tumor, local control ratio of 6 months, survive rate in 2 years, the median survival time between A and B groups (P <0.05). There was significant difference in the rate of AFP degrade between A and B groups (P<0.05) postoperative. There is 13,17examples respectively in A group the rate of AFP degrade<50%,>50%, and B group 5,25 respectively. And there was a great quantity of coagulation necrosis of tumor focus in A group pathology postoperative, but a great quantity of lipoid degeneration necrosis in B group pathology postoperative. It was higher of CD3, CD4, CD4/8 in postoperative than in preoperative of both A and B groups. There was significant difference of CD3, CD4, CD4/CD8 between preoperative and postoperative in both A and B groups (P<0.05). And significant difference between A and B group postoperative exclude CD8 (P< 0.05). It was higher of immune globulin in postoperative than in preoperative of both A and B groups. But there was no significant difference between postoperative and preoperative of A group (P>0.05); immune globulin exclude C3significant difference between postoperative and preoperative of B group (P<0.05). It was no less in A group than in B group of the apoptosis percentage in normal tissue. There was no significant difference of the apoptosis percentage in normal tissue between A and B group (P>0.05). But it was higher in A group than in B group of the necrosis percentage in tumor edge. There was very significant difference of the necrosis percentage in tumor edge between A and B group (P<0.01). It was higher in B group than in A group of the apoptosis percentage in tumor edge. There was very significant difference of the apoptosis percentage in tumor edge between A and B group(P<0.05).
Conclusions
There was no less influence on humoral-mediated immunity in single TACE than associated with percutaneous chemotherapic agents lipiodol emulsion injection to make interstitial therapy in liver cancer. This sequence method of treatment could improve cell-mediated immunity and humoral immune function to much more extent. Transcatheter arterial chemoembolizaton combined with interstitial therapy of percutaneous lipiodol and anti-cancer agents injection intratumorly for liver cancer may improve the percent of lipiodol deposited in the tumor, local control ratio of 6 months, and to extend life span, to drop recurrence rate of remained focus tumor, to relieve adverse effect postoperative. So inducing the tumor cell apoptosis and improving immune function by TACE associated with interstitial therapy is the one of the major mechanisms treating liver cancer possibly.
原发性肝癌(HCC)的发生发展是一个多因素、多阶段、多基因变异的复杂过程,与机体的免疫状况密切相关,尤其是与T细胞的细胞免疫有关,但受多种因素的调节,肿瘤患者的机体免疫功能不同程度地发生紊乱。多数学者认为在机体的抗肿瘤免疫中细胞免疫占主导地位,研究表明,T淋巴细胞和NK细胞的比例及功能变化与肿瘤的发展、扩散有明显的相关性。有研究表明HCC患者外周血中CD3,CD4降低,CD8增高,免疫功能低下,恶变细胞所产生的免疫抑制是肿瘤患者免疫功能低下的主要原因。
肿瘤免疫主要与T淋巴细胞的细胞免疫有关,T淋巴细胞亚群是反映机体细胞免疫功能的一个指标。T淋巴细胞是由不同亚群组成的,外周血T细胞亚群在数量上的协调比例,特别是CD4/CD8的比值是反映细胞免疫平衡与否的敏感指标,有助于反映机体免疫反应的调节能力。其中CD4+T淋巴细胞一般认为处于细胞免疫的核心,以其主要分泌细胞因子调节肿瘤免疫被称之为辅助性T淋巴细胞(Th),Th是人类主要组织相溶性抗原(MHC)Ⅱ类分子限制性T细胞,由于大多数肿瘤细胞不表达MHCⅡ类分子,故此类分子不能直接识别肿瘤细胞,而是依赖抗原提呈细胞如B细胞、巨噬细胞提呈相关抗原,对之进行特异性激发后,才分泌淋巴因子(如IL-2、r-干扰素等),激活B细胞、巨噬细胞、NK细胞,并通过其活化的细胞发挥抗肿瘤作用。Ts细胞(suppressor T cell)即抑制性T细胞在宿主免疫机制中起着复杂的抑制调控作用。当发生肿瘤后,Ts在功能和数量上都显著增强,抑制机体对肿瘤的免疫效应,从而使肿瘤逃逸机体的免疫监视,促进了肿瘤的生长。大量体外实验证实,Th和Ts细胞在正常情况下保持着恒定的比值,某一亚群变化可直接影响到群体功能,两者相互制约构成机体重要的免疫调节机制。
肝癌的发生发展也同时与细胞凋亡存在着密切的关系,体外培养的肝癌细胞和体内发生的肝癌细胞均存在着细胞凋亡现象。未经治疗的肝癌会发生自发性癌细胞凋亡,恶性程度越高凋亡指数越大。肝癌时肿瘤细胞的增殖指数与凋亡指数呈正相关,从正常肝脏、癌前病变到肝癌,凋亡率随增殖率增高而增高,但其增高的幅度明显小于细胞增殖增高的幅度。肝癌组织中肿瘤细胞凋亡明显高于正常肝组织及癌周肝组织。细胞凋亡在肿瘤的发生发展中可能具有双面作用：细胞凋亡可能抑制癌细胞生长；也可能通过凋亡筛除那些生命力低下或表型类似正常细胞的肿瘤细胞,而选择侵袭力强增殖旺盛的细胞克隆,促进肿瘤发生发展。所以研究细胞凋亡的机制及凋亡在疾病过程中的作用,不但可以了解肿瘤发生发展的机理,更重要的是从一个全新的角度认识肿瘤细胞的生物学特性,为肿瘤治疗开辟新的途径提供了重要的理论依据。
选择经肝动脉化疗栓塞术(transcatheter arterial chemoembolizaton, TACE)是不能切除肝癌公认的首选治疗方法,经肝动脉化疗栓塞治疗肝癌后,肿瘤细胞被杀死,肿瘤组织出现凝固性坏死,肿瘤细胞负荷减少,使肿瘤释放的TNF减少,免疫抑制因子的产生亦大大减少,减弱了对机体的免疫功能的影响,机体免疫细胞指标有所改善。经手术和栓塞治疗后肝癌患者的免疫功能受抑减轻。但肝动脉化疗栓塞治疗常包括栓塞和化疗两部分,化疗则抑制机体的免疫功能,所以对机体免疫功能的影响颇为复杂。
另一方面,一般认为TACE作用机制是局部化疗和血管栓塞引起了肿瘤组织细胞坏死,但近年来发现栓塞引起的缺血缺氧是肿瘤细胞凋亡强有力的基因诱导动因,缺血数分钟就有即刻早期基因表达,缺氧也可以诱导凋亡基因表达增高,缺血至少可诱导80种以上的基因表达,包括促进细胞凋亡基因表达增高,抑制凋亡基因表达下降,使未凝固坏死的肝癌肿瘤细胞发生凋亡。因此,凋亡在TACE治疗肝癌所引起的肿瘤组织死亡中具有重要的作用,并且有可能是TACE治疗肝癌的其中一重要机制。
但由于肝癌易转移和复发特性,任何单一治疗手段均不满意。选择经肝动脉化疗栓塞术后,但仍有大量病例常存在瘤灶栓塞不充分,TACE时经血管内注入的栓塞剂-碘油化疗药物混合乳剂少,致使瘤灶内碘油化疗药物沉积不充分,无碘油沉积部分病灶则在短期内快速增生,是此类肝癌患者治疗失败和局部复发进展的主要原因。近年,有研究直接将细胞毒药物或生物制剂直接植入肿瘤组织或其周围的间质组织内,对肿瘤细胞进行直接攻击的方法,即经皮穿刺瘤内抗癌药物注射间质治疗(interstitial therapy, IT)。在肿瘤局部缓慢释放,持续保持较高的浓度,杀灭肿瘤细胞,即为缓释化疗(slow-release chemotherapy)。
碘油是一种碘含量37%-39%的脂肪酸乙脂亚麻子油,不透X线,具有X线透视下适时监测其弥散范围的优点,同时能选择性地较长时间滞留在肝肿瘤组织中,不像大多数生物载体那样在体内易被降解或失去活性,也不会因癌细胞突变而失去特异性,可以作为较好的载体进行瘤内药物注射。碘油作为粘稠的油性液体,可以完全包围癌细胞阻碍癌细胞与组织液进行物质交换及氧的获取,使细胞水肿和脂肪变性,重度持续缺氧引发细胞凋亡和死亡。
目前仅有少量文献报道经皮肝穿刺瘤内注入碘油化疗药物乳剂进行肿瘤间质治疗肝癌的临床研究,其中对肝癌患者免疫功能的影响、诱导肿瘤细胞凋亡的基础研究甚少。我们采用TACE联合经皮肝穿刺瘤内注射碘油化疗药物,进行肿瘤间质治疗,一方面探讨该序贯治疗模式的临床疗效及其病理变化,一方面通过流式细胞仪(FCM)检测外周血T淋巴细胞亚群免疫功能的变化,所诱导的肿瘤细胞凋亡变化,初探其对免疫功能的影响、诱导肿瘤细胞凋亡在该治疗模式中的作用,并预期是其重要的治疗机制之一。我们将该治疗模式的临床研究和基础研究结合在一起,这是本研究的特色创新之处,尚未见类似报道。
目的
研究单纯经肝动脉化疗栓塞(transcatheter arterial chemoembolizaton,TACE)联合经皮肝瘤内碘油化疗药物注射肿瘤间质治疗(interstitial therapy, IT)肝癌的临床疗效,病理变化,介入术前后肝癌患者外周血T淋巴细胞亚群及免疫球蛋白的变化及意义。探讨联合肿瘤间质治疗后诱导肝癌肿瘤细胞凋亡的变化及其在肿瘤治疗中的作用机制和意义。
材料与方法
将60例肝癌患者分成两组,对照组(A组)30例行单纯TACE治疗,实验组(B组)30例行TACE联合经皮肝瘤内药物注射碘油化疗药物肿瘤间质治疗。观察患者术后发热等不良反应,术前及术后1周抽取2组患者外周血,常规检测血常规、肝肾功能,观察其变化,术后两月复查和随访,观察2组患者术后一月瘤灶内碘油沉积情况以及术后半年肿瘤局控率,1、2年生存率以及中位生存期。应用流式细胞术检测外周血T淋巴细胞亚群(CD3+T、CD4+T、CDS+T、CD4+T/CD8+T),检测免疫球蛋白和补体C3、C4水平变化,观察免疫功能的改变。术后一月肿瘤穿刺活检取材,病理染色观察病理改变：采用流式细胞仪Annexin-V/PI双染法检测,观察肿瘤细胞凋亡率、死亡率。
结果
A组患者术后体温正常者7例,低度发热者3例、中度发热7例、高度发热13例,B组体温正常16例、低度发热8例、中度发热4例、高度发热2例,χ2检验两组比较有显著性统计学差异,P<0.01。配对t检验显示B组白细胞、血红蛋白术前术后差值明显低于A组,两组比较有显著性统计学差异,P<0.01,B组血小板术前术后差值低于A组,有统计学差异,P<0.05。术后A组白细胞明显高于B组,两组比较有显著性统计学差异,P<0.01；术后A组血小板、血红蛋白要低于术后B组,但两组比较无统计学意义,P>0.05。配对t检验显示B组谷丙转氨酶、谷草转氨酶术前术后差值明显低于A组,两组比较有显著性统计学差异,P<0.01,B组总胆红素指数术前术后差值低于A组,有统计学差异,P<0.05,B组血白蛋白术前术后差值低于A组,但两组间比较无统计学差异,P>0.05。术后A组谷丙转氨酶、谷草转氨酶、总胆红素指数均明显高于B组、血白蛋白明显低于B组,两组比较有显著统计学差异,P<0.05。配对t检验显示B组血尿素氮术前术后差值低于A组,两组比较有统计学差异,P<0.05；B组血肌苷术前术后差值低于A组,但无统计学意义,P>0.05。术后尿素氮、肌苷A组均高于B组,但两组比较无统计学意义,P>0.05。A组手术后碘油沉积率于<50%、50-75%、>75%范围者各为8、12、10例；B组分别为0、12、8例,A、B两组手术后碘油沉积率比较有显著性统计学差异,P<0.05；A组手术后甲胎球蛋白降低率于<50%、>50%范围者各为13、17例,B组分别为5、25例,A、B两组甲胎球蛋白比较有统计学差异,P<0.05(见表5)。A组手术后肿瘤缩小率于<25%、25%-50%、50-75%、>75%者各为23、6、1、0例；B组分别为17、12、1、0,但A、B两组比较无统计学意义,P>0.05。A组手术后6个月复查稳定无复发进展的为12例,复发进展的为18例；B组分别为20、10例,A、B两组手术后6月局控率相比较有统计学差异,P<0.05。A组1,2年生存率80%,43%,中位生存期20.5月。B组1、2年生存率90%,60%,中位生存期22月。外周血T淋巴细胞亚群的结果显示A组单纯经肝动脉化疗栓塞肝癌患者,手术后一周CD3、CD4及CD4/CD8升高,CD8降低,手术前后CD4及CD4/CD8差异有显著性(P<0.05),CD3、及CD8则无统计学差异；B组联合肿瘤间质治疗后,其外周血T淋巴细胞较A组变化更为明显,手术前后CD3、CD4及CD4/CD8升高,CD8降低,手术前后具有非常显著性统计学差异(P<0.01),且A、B两组术后比较,除CD3外统计学亦有显著性差异(P<0.05)。免疫球蛋白和补体检测结果,A组术后免疫球蛋白和补体有所升高,以IgG、IgA、C4升高明显,手术前后有显著性统计学差异,(P<0.05),但IgM、C3手术前后无显著性统计学差异(P>0.05)；B组手术前后仅IgG有所升高,具有显著性统计学差异(P<0.01),IgA、IgM、C3、C4无显著性统计学差异(P>0.05),B组IgG、IgM手术前后差值较A组升高,有显著性统计学差异(P<0.05), IgA、C3、C4无显著性统计学差异(P>0.05)。A组瘤灶病理以大量肿瘤细胞凝固性坏死改变为主,B组则可见大量肿瘤细胞脂肪样变性坏死。A、B两组患者正常肝脏组织流式细胞仪Annexin V/PI双染法凋亡率相比较无统计学意义；两组正常肝脏组织的坏死率比较也无统计学意义；B组患者肿瘤组织凋亡率显著高于A组,两组相比较有统计学差异,P<0.05；A组肿瘤边缘组织死亡率显著高于B组,两组死亡率比较有显著性统计学差异,P<0.01。
结论
TACE联合肿瘤间质注射碘油化疗药物治疗肝癌,可以显著提高瘤灶碘油沉积率,提高肿瘤局控率,降低TACE术后残留瘤灶复发率,延长患者生存期,减轻介入术后不良反应。单纯TACE治疗肝癌增强患者细胞免疫功能,对体液免疫影响较小。联合瘤内碘油化疗药物乳剂注射肿瘤间质治疗的方法可以更大程度改善患者细胞免疫和体液免疫功能。经动脉化疗栓塞诱导大量癌细胞进入凋亡,是TACE联合瘤内药物注射碘油化疗药物肿瘤间质治疗肝癌的重要机制,该治疗模式可以促进肝癌细胞凋亡,对于进一步提高肝癌的疗效具有积极的意义,而其所引致的急性凝固性坏死改变、大量急性肿瘤溶解坏死等不良反应较少,因此是一种相对安全、稳妥、有效、和具有前景的肝癌治疗模式。
Background
The development of primary hepatic carcinoma is a process with multiple factor, multiple stage, polygenic variation, close correlated with immune state, especially T lymphocyte cell. The process is regulated by multiple factor, accompanied with confused immune state to some extent. Majority scholar think that cell mediated immunity occupy the master position in immune. Some research showed the proportion and metergasis of T lymphocyte cells and NK cells are close related with the development and diffusion of tumor. And some research showed that of T lymphocyte subsets in peripheral blood in patients with HCC, CD3 and CD4 degraded, CD8 increased, immune function was weak, that was the major cause of weak immune of which tumor cells resulted in immune suppression.
Tumor immunity is related with T lymphocyte cell mediated immunity in major, which reflect organism immune function. T lymphocyte subsets are consist of different subsets, especially CD4/CD8. It is the sensitive reflection against the balance of cell mediated immunity. CD4+T lymphocyte cells are the core of the cell mediated immunity, which regulate immunoreactive function by excreting cytokine, named helper T lymphocyte. Th is the restriction T lymphocyte of major histocompatibility antigen(MHC)classⅡmolecule. Because most tumor cells do not present MHCⅡ, this kind molecule do not direct identify tumor cells, but rely on antigen presenting cell, such as B lymphocyte, macrophagus to present related antigen and secret lymphokine, interleukin-2, r-interferon, and so on, so that activate B lymphocyte, macrophagus, NK cell to play its effective resisting tumor.
Substantial evidence that has been expressed indicates that the cell apoptosis is related with the development of the tumor, the occurrence of the tumor closely, and hepatoma carcinoma cells cultured in vitro and esoteric all existed phenomenon of apoptosis. Spontaneous malignant cell apoptosis happened to hepatoma untreated, and malignancy to much more extent, higher index of apoptosis. It is positive correlation between proliferation index and apoptotic index in liver cancer. From normal liver to lesion precancerous and hepatoma, apoptosis percentage increased as proliferation increased. It is obviously higher of apoptosis in liver cancer tumor tissue than in the normal liver tissue. There are two sides of apoptois probably, one side restraining growth, another eliminating weak vitality tumor cells so that strong invasiveness tumor cells cloning and developing. So to study the mechanism and effectiveness of apoptosis could supply an important theory basis on new pathway of tumor treatment.
Primary hepatic carcinoma is one of the most common malignant tumors in our country. Any single therapeutic tool is not satisfactory with liver cancer for the characteristic of easy metastasis and recurrence. Transcatheter arterial chemoembolizaton, TACE, is the first of chosen treatment methods, but there are still insufficenicy of embolization in many cases which lipiodol chemotherapeutics emulsion deposited in tumor focus is not enough so that rapid hyperplasy in tumor focus without lipiodol deposited. So it is the major cause of treatment failure and recurrence progression in local tumor region to the patients with liver cancer. There were any investigations implanting cytotoxic drug or biological agents directly into tumor tissue or peripheral interstitial substance recently, that is interstitial therapy, IT, forming the slow-release chemotherapy which killed tumor cells in local tumor region by slow released chemotherapy and sustained high concentrate agents.
Transcatheter arterial chemoembolizaton, TACE, is the first selection to unable removal hepatoma. After TACE, a large amount of tumor cells were killed, coagulation necrosis in tumor appeared and tumor cell burden alleviate, so immune suppression factors, TNF, decreased and weakened its influence to immune function. But Transcatheter arterial chemoembolizaton include chemo and embolization which make influence to organism immune function complex.
Lipiodol is a kind of fatty acid aethyl conjulin with iodine contents about 37%-39%. There is property of lipiodol not penetrated by X-ray, monitoring its diffusion scope at the proper moment through X-ray, being detained long term in tumor tissue, not easy to be missing activity and specificity for tumor cell mutation. So lipiodol is a better carrier adapted to injection into tumor, it can surround tumor cell to hinder material and oxygen exchange, then make cells hydropsia, fatty degeneration and death. But there were only few basic researches about percutaneous chemotherapic agents lipiodol emulsion injection.
On another respect, common standpoint of the mechanism of TACE is that local chemoembolization bring up the tumor cells necrosis. But recently it was found that ischemic and oxygen deficiency were the reason of inducing tumor cells apoptosis, immediate early gene expression for several minutes after ischemic and oxygen deficiency. Ischemic and oxygen deficiency could induce more than 80 gene expression including that expression of gene promoting apoptosis increases and expression of gene restraining apoptosis descend. So apoptosis play an important role in tumor tissue necrosis due to TACE in patients with hepatoma. And it is an important mechanism to TACE probably of the apoptosis induced by TACE.
We combined TACE with percutaneous chemotherapic agents lipiodol emulsion injection to make interstitial therapy in liver cancer, in order to approach the clinic curative effect of this sequential therapy and pathological change in one side, to explore the characteristics and significances in immunology changes of blood subgroups of lymphocyte T, to explore significances and effective of the tumor cell apoptosis induced by the treatment method in another side. We got the clinic research and basic research together, that is special feature, new ideals in our study, and not yet reported.
Objective
To study the clinic curative effect by transcatheter arterial chemoembolizaton combined with interstitial therapy for liver cancer and pathological change first, to explore the characteristics and significances in immunology changes of blood subgroups of lymphocyte T, to explore significances and effective of the tumor cell apoptosis induced by the this sequential therapy secondly.
Methods
60 patients with liver cancer were divided into two groups, A group received transcatheter arterial chemoembolizaton, and B group received transcatheter arterial chemoembolizaton combined with interstitial therapy of percutaneous lipiodol and anti-cancer agents injection intratumorly for liver cancer. Then to observe the percent of lipiodol deposited in the tumor, local control ratio of 6 months, survive rate in 2 years, the median survival time, adverse effect, and puncher biopsy one month postoperative. T lymphocyte cell subsets, CD3+, CD4+,CD8+, CD4+/CD8+ in the peripheral blood before and one week after operation were measured by flow cytometry; immune globulin determined by single radial immunodiffusion. The apoptosis percentage, death percentage of tumor cells was measured by flow cytometry with Annexin V/PI staining.
Results
There was significant difference in the percent of fever between two groups, P< 0.01, normal temperature 7 instances in A group, low fever 3 instance, middle lever 7 instances, high lever 13 instances; normal temperature 16 instances in B group, low fever 8 instance, middle lever 4 instances, high lever 2 instances. There was no significant difference of WBC, HB, PLB preoperative in both A and B groups (P> 0.05).There was significant difference of WBC, HB between preoperative and postoperative in both A and B groups (P<0.05). And significant difference of WBC, HB between A and B group postoperative (P<0.05). It was higher of WBC in A group preoperative than postoperative, there was significant difference, P<0.05, but in B group there was no significant difference, P>0.05. And it was higher of HB in A group preoperative than postoperative, there was significant difference, P<0.05, but in B group there was no significant difference, P>0.05. There was significant difference in the percent of lipiodol deposited in the tumor, local control ratio of 6 months, survive rate in 2 years, the median survival time between A and B groups (P <0.05). There was significant difference in the rate of AFP degrade between A and B groups (P<0.05) postoperative. There is 13,17examples respectively in A group the rate of AFP degrade<50%,>50%, and B group 5,25 respectively. And there was a great quantity of coagulation necrosis of tumor focus in A group pathology postoperative, but a great quantity of lipoid degeneration necrosis in B group pathology postoperative. It was higher of CD3, CD4, CD4/8 in postoperative than in preoperative of both A and B groups. There was significant difference of CD3, CD4, CD4/CD8 between preoperative and postoperative in both A and B groups (P<0.05). And significant difference between A and B group postoperative exclude CD8 (P< 0.05). It was higher of immune globulin in postoperative than in preoperative of both A and B groups. But there was no significant difference between postoperative and preoperative of A group (P>0.05); immune globulin exclude C3significant difference between postoperative and preoperative of B group (P<0.05). It was no less in A group than in B group of the apoptosis percentage in normal tissue. There was no significant difference of the apoptosis percentage in normal tissue between A and B group (P>0.05). But it was higher in A group than in B group of the necrosis percentage in tumor edge. There was very significant difference of the necrosis percentage in tumor edge between A and B group (P<0.01). It was higher in B group than in A group of the apoptosis percentage in tumor edge. There was very significant difference of the apoptosis percentage in tumor edge between A and B group(P<0.05).
Conclusions
There was no less influence on humoral-mediated immunity in single TACE than associated with percutaneous chemotherapic agents lipiodol emulsion injection to make interstitial therapy in liver cancer. This sequence method of treatment could improve cell-mediated immunity and humoral immune function to much more extent. Transcatheter arterial chemoembolizaton combined with interstitial therapy of percutaneous lipiodol and anti-cancer agents injection intratumorly for liver cancer may improve the percent of lipiodol deposited in the tumor, local control ratio of 6 months, and to extend life span, to drop recurrence rate of remained focus tumor, to relieve adverse effect postoperative. So inducing the tumor cell apoptosis and improving immune function by TACE associated with interstitial therapy is the one of the major mechanisms treating liver cancer possibly.
引文
[1]吴孟超.原发性肝癌的诊断和治疗进展.中国肿瘤；1999,8(Ⅰ)：18-20
[2]汤钊酞主编.肝癌转移复发的基础与临床.上海,上海科技教育出版社.2003：1-51.
[3]汤钊酞.原发性肝癌的研究进展。中国肿瘤临床,1998,25(2)：137-141.
[4]吴孟超.原发性肝癌治疗的进展及展望.第二军医大学学报,2002,23：1-4.
[5]张积仁.Cryocare氩氦靶向肿瘤治疗技术.生物医学工程研究,2005,24(2)：28-32
[6]张积仁.氩氮刀冷冻消融治疗肿瘤[J].中国肿瘤,2007,16(5)：335-337.
[7]吴孟超,陈汉,沈锋,等.微创在肝癌外科治疗中的地位.中国微创外科杂志,2002,2：69-70.
[8]Lau WY, Leung TW, Yu SC, et al. Percutaneous local ablativetherapy for hepatocellular carcinoma:a review and look into the future. Ann Surg,2003, 237:171-179.
[9]Goldstein HM, Wallace S, Anderson J H, et al. Transcatheter occlusion of abdominall tumors. Radiology,1976;120 (3):539-545.
[10]陈勇.一种新的消融剂—碘油化疗药乳剂的临床应用研究.南方医科大学,博士学位论文,2007.
[11]Lin SM, Lin CJ, Lin CC, et al. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less.Gut,2005,54:1151-1156.
[12]陈敏华,严昆,杨薇,等.343例肝恶性肿瘤射频消融疗效及并发症.北京大学学报(医学版)2005,37(3)：292-296.
[13]Ja Kyung Kim, Kwang-Hyub Han, Jong Tae Lee, et al. Long-term Clinical Outcome of Phase Ⅱb Clinical Trial of Percutaneous Injection with Holmium-166/Chitosan Complex (Milican) for the Treatment of Small Hepatocellular Carcinoma. Clinical Cancer Research,2006,12 (2):543-548.
[14]颜红兵,郑广生,吴铁墉.原发性肝癌的经皮酒精注射治疗.中国临床医生,2001,29(4)：24-25.
[15]林红军,张峰.超声引导下无水酒精注射治疗肝癌80例分析.南京医科大学学报(自然科学版),2002,22(6)：521-522.
[16]Fartoux L, Arrive L, Andreani T, et al. Treatment of small hepatocellular carcinoma with acetic acid percutaneous injection. Gastroenterol Clin Biol, 2005,29 (12):1213-1219.
[17]牛俊波.恶性实体肿瘤间质治疗进展.外科理论与实践,2008,13(1)：82-84.
[18]陈翼.原发性肝癌瘤内注射治疗进展.重庆医学,2005,34(11)：1734-1736.
[19]毛军杰.经皮瘤内药物注射治疗肝癌.放射学实践,2008,23(2)：221-223.
[20]Sugiura N. Percutaneous int ratumoral injection of ethanolunder ultrasound imaging for treatment of small hepatocellular carcinoma[J]. Aata Hepatol J PN,1983,30:43.
[21]Livraghi T,Bolondi L. No treatment, resection and ethanol in hepatatocellular carcinoma [J]. J Hepatol,1995,22:522.
[22]Kanaka K,Nakamura,Nuimata K, et al. The long term efficacy of combined transcatheter arterial embolization and percutaneous ethanol injection in the treatment of patient with large hepatocellular carcinoma and cirrhosis[J]. Cancer,1998,82:78
[23]Ohnishi K,Ohyama N, Ito S,et al. Small hepatocellular carcinoma:treatment with US-guided intratumoral injection of acetic[J]. Radiology,1994,193:747
[24]Ohnishi K, Yoshika H, Ito S,et al. Prospective randomised controlled trial comparing percutaneous acetic acid injection and percutaneous ethanol injection for small hapatocellular carcinoma[J]. Hepatology,1998,27:67
[25]黄雯霞.肝内注射华蟾素之治疗肝癌18例初步观察[J].癌症,1990,9(3)：239
[26]冯晓灵,蒋亚生,李柏.肝癌局部注射丝裂霉素与中药肝复康的临床及实验对照分析[J].肿瘤,1994,14：291
[27]杨敏一,梁宝英,余清平,等.B超导向瘤体中心注射去甲基斑蝥素治疗中晚期肝癌41例[J].人民军医,1993,6(9)：44
[28]李浩,祖茂衡.超液化碘油瘤内注射对肝癌细胞作用的实验研究.中国介入影像与治疗学2007,4(5)：383-387.
[29]李华,潘承恩,刘清光,等.Bcl-2, C-myc在肝细胞癌中的表达及临床意义[J].西安医科大学学报,2000；21(2)：152-155.
[30]赵爱志,窦科峰,李开宗,等.肝细胞肝癌中血管内皮生长因子及nm232H1蛋白的表达[J].第四军医大学学报,2000；21(11)：1336-1337.
[31]贾宗良,白建华,王清丽.甲状腺癌患者血清中SIL 22R测定的临床意义 [J].西安医科大学学报,2000；21(2)：164-165.
[32]马列婷,王亚文,李影,等.肝细胞肝癌患者介入治疗后免疫功能的改变.第四军医大学学报,2002；23(8)：3201.
[33]曹驰,李青,梁颖,等.原发性肝癌介入治疗后机体免疫功能的研究.中国医师杂志2005,7(7)：903-905.
[34]Yasutomo K. The cellular and molecularmechanism of CD4/CD8 lineage commitment [J]. J Med Invest,2002,49 (1-2):1-6.
[35]赵志伦,刘永雄,宋子信.肝癌病人化疗栓塞前后LAK细胞活性变化的研究[J].中国肿瘤临床,1996,23(1)：27-30.
[36]曹驰,李彩霞.原发性肝癌的免疫状态与预后的相关性分析[J].肿瘤防治杂志,2004,38(2)：127-130.
[37]陈伟强,张世能.肝癌患者治疗前后T细胞亚群和sIL-2R水平的变化[J].上海免疫学杂志,1998,18(4)：238-240.
[38]Akizuki S, Magara T, Tanaka T. Diminution of the number of gamma delta T lymphocytes in hepatocellular carcinoma patients treated with transcatheter arterialembolization[J]. Nihon-Kinsho-Meneki-Gakkaikaishi,1998,21(3) 108-117.
[39]尹燕明,秦庆亮,张伟等.肝细胞癌热休克蛋白70过表达与自发性癌细胞凋亡[J].中华肝脏病杂志,2001,9(2)：84.
[40]Hino N, Higashit, Nouso K,et al.Apoptosis and proliferation of human hepatocellular carcinoma[J].Liver,1996,16:123.
[41]王冠军,李薇,续哲莉..原发性肝细胞癌细胞凋亡的研究[J].吉林医学,1 999,20(4)：195.
[42]陈胜利.人肝细胞癌细胞凋亡.现代临床医学生物工程学杂志,2002,8(6)：459-462.
[43]肖恩华.细胞凋亡与肝癌.国外医学临床放射学分册,1999,1：9-12.
[44]肖恩华,胡国栋.化疗栓塞后肝细胞癌细胞凋亡和耐药基因表达的改变.放射学实践,2000,1 5(6)：387-389.
[45]吴沛宏.肿瘤微创治疗展望.介入放射学杂志,2005,14(6)：561-562.
[46]张智坚,吴孟超,陈汉,等.经皮肝穿刺射频热凝与肝动脉化疗栓塞联合治疗肝细胞癌.中华外科杂志,2002,40：826-829.
[47]Rossi S, Garbagnati F,Lencioni R, et al. Percutaneous radiofrequency thermal ablation of nonresectable hepatocellular carcinoma after occlusion of tumor blood supply. Radiology,2000,217:119-126.
[48]Lu DS, Raman SS, Limanond P, et al. Influence of large peritumoral vessels on outcome of radiofrequency ablation of liver tumors. J Vas Interv Radiol, 2003,14:1267-1274.
[49]蒋小良,牟培源,李永忠.碘油治疗肝癌的研究进展.现代肿瘤医学,2006,14(1)112-113.
[50]Livraghi T. Percutaneous ethanol injection in the treatment of hepatocellular carcinoma in cirrhosis [J]. Hepatogastroenterology,2001,48:20.
[51]Yoon HK,Song H Y,Sung KB,et al. Percutaneous hot saline injection therapy:effectiveness in large hepatocellular carcinoma[J]. J Vasc Interv Radiol,1999,10:477.
[52]Huang J F, Kuang M,Lu M, et al. Percutaneous hyperthermal distilled water injection therapy (PHDT) for liver cancer [J]. Asian J Surg,1999,22:337.
[53]Gerolami R, Cardoso J,Lewin M, et al. Evalution of HSV2tk gene therapy in a rat model of chemically induced hepatocellular carcinoma by int ratumoral and intrahepatic artery routes[J]. Cancer Res,2000,60:993.
[54]Seol J G,Heo DS,Kim HK,et al. Selective gene expression in hepatic tumor with t rans2arterial delivery of DNA/liposome/transferring complex [J]. In Vivo,2000,14:513.
[55]陈喆.去甲基斑蝥素2泊洛沙姆407缓释剂和无水乙醇的肝癌瘤内注射疗效比较[J].第二军医大学学报,2001,22(7)：606.
[56]戚晓军,赵海东,高文斌,等.三氧化二砷瘤内注射联合肝动脉化疗栓塞治疗肝癌[J].肿瘤学杂志,2003,9(3)：147.
[57]林礼务,何以敉,高上达,等.复方中药经皮瘤内注射诱导肝细胞癌凋亡[J]中国医学影像技术,2002,18(1)：6.
[58]孙铭,朱争艳,方淑昌,等.中药硇砂提取液裸小鼠肿瘤内注射治疗肝癌的实验研究[J].肿瘤防治研究,2002,29(5)：365.
[59]王建平,侯鲁强,刘军伟.肝癌碘油栓塞后碘油沉积量与疗效的相关性.实用医药杂志,2008,25(3)：308.
[1]陈尉峰,主编.医学免疫学[M]。第3版.北京：人民卫生出版社,2002.230-234.
[2]杨镇.肿瘤免疫学[M].第一版,武汉：湖北科学技术出版社,1998：31-45.
[3]余传霖,叶天星,陆德源,等主编.上海：上海医科大学出版社,.现代医学免疫,1997：1022.
[4]Kuss I, Hathaway B, Ferris RL, et, al. Decreased absolute counts of T lymphocyte subsets and their relation to disease in squamous cell carcinoma of the head and neck [J]. Clin CancerRes,2004,10 (11):3755-3762.
[5]Hang K, Hayashi R, Blond—Walker A, et al.The central role of CD4+T cells in the antitumor immune response[J].J Exp Med,1998,188(12): 2357-2368.
[6]李国玲,林华笙,韩雪飞,等.恶性肿瘤患者的免疫学变化[J].中华临床新医学,2004,4(1)：9-10.
[7]乌玉辉,申正堂,海健,等.乳腺癌患者细胞免疫功能的检测[J].中国医师杂志,2001,3(8)：627-628.
[8]刘莉,丁乾,曹如波,等.恶性肿瘤患者外周血CD4+CD25+调节T细胞的检测及其临床意义.临床肿瘤学杂志2005,10(4)：342-345.
[9]龚非力,主编.医学免疫学[M].第2版.北京：科学出版社,2005：390-399.
[10]杨辉.肺癌患者免疫状态的综合评价及化疗对其免疫状态的影响.军事科学医学院,硕士学位论文,2003.
[11]Ormandy LA, Hillemann T, Wedemeyer H, et al. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma[J].Cancer Res,2005,65 (6):2457-2464.
[12]Kamohara Y, Kanematsu T. Treatment of liver cancer:current status and future prospectives [J]. Gan to Kagaku Kyoho,2000,27(7):987-992.
[13]巴德年主编.当代免疫学技术与应用.北京医科大学中国协和医科大学联合出版社.1998：8-12.
[14]陈复兴,刘军权,周忠海,等.癌症患者T细胞亚群的临床意义[J].细胞与分子免疫学杂志,2002,18(1)：55.
[15]周信达.肝癌诊治的若干进展及展望[J].中华消化杂志,1999,19(1)：5-7.
[16]牛俊波.恶性实体肿瘤间质治疗进展.外科理论与实践,2008,13(1)：82-84.
[17]陈翼.原发性肝癌瘤内注射治疗进展.重庆医学,2005,34(11)：1734-1736.
[18]毛军杰.经皮瘤内药物注射治疗肝癌.放射学实践,2008,23(2)：221-223.
[19]Akizuki S, Magara T, Tanaka T. Diminution of the number of gamma delta T lymphocytes in hepatocellular carcinoma patients treated with transcatheter arterial embolization [J]. Nihon-Kinsho-Meneki-Gakkaikaishi,1998, 21(3):108-117
[20]韩秀婕,董宝玮,梁萍,等.微波治疗肝癌后局部细胞免疫变化及其对临床疗效影响.中国癌症杂志,2007,17(2)：135-138.
[21]Doherty DG, Ofarrelly C. Innate and adaptive lymphoid cells in the human liver[J]. Immunol Rev,2000,174 (4):5-20.
[22]Seki S, Habu Y, Kawamura T, et al. The liver as a crucial organ in the first line of host defense [J]. Immunol Rev,2000,174 (4):35-46.
[23]Cole WH, Humphrey L. Need for immunologic stimulators during immunosupp ression produced by major cancer surgery[J]. Ann Surg,1985,202 (1):9220.
[24]Litton MJ, Dohlsten M, Rosendahl A, et al. The distinct role of CD4+ and CD8+T cell during the antitumor effects of targeted superantigens[J]. Br J Cancer,1999,81 (2):359-366.
[25]张志培,施新猷,李六金,等.接种9724肿瘤细胞后不同免疫力小鼠体内T细胞的作用[J].中国肿瘤生物治疗杂志,2001,8(2)：1182121.
[26]牟培源,董宝玮,梁萍,等.超声引导高聚生瘤区注射在肝癌介入治疗中的临床应用评价.中国肿瘤临床,2002,29(11)：797-798,801.
[1]Kerr JF,Wyllie AH,Currie AR.Apoptosis:a basic biological phenomenon with wide-ranging implication in tissue Kinetics.Br J Cancer,1972,26(4):239-257.
[2]Thompson CB.Apoptosis in the pathogenesis and treatment of disease. Science,1995,267(5203):1456-62.
[3]Evan G,Littlewood T.A matter of life and cell death. Science,1998,281: 1317-1321.
[4]张学军,郭礼和.细胞凋亡失调与疾病的关系研究.中华医学杂志,1998,78(8)：565-566.
[5]尹燕明,秦庆亮,张伟等.肝细胞癌热休克蛋白70过表达与自发性癌细胞凋亡[J].中华肝脏病杂志,2001,9(2)：84
[6]Hino N,Higashi t,Nouso K, et al. A poptosis and proliferation of human hepatocellular carcinoma[J].Liver,1996,16:123
[7]王冠军,李薇,续哲莉.原发性肝细胞癌细胞凋亡的研究[J].吉林医学,1999,20(4)：195
[8]陈胜利,张静.人肝细胞癌细胞凋亡[J].现代临床医学生物工程学杂,2002,8(6)459-462
[9]Akins PT,Liu PK, Hsu CY,et al. Immediate early gene expression in response to cerebral ischemia. friend or foe? Stroke,1996,27:1682-1687.
[10]An WG, Kanekal M, Simon MC, et al. Stabilization of wild2type p53 byhypoxia-inducile factor 1α. Nature,1998,392:405-408.
[11]陈胜利,徐兆栋.兔VX2肝癌模型与实验性肝癌介入治疗.现代临床医学生物工程学杂志.2003,9(4)：371-373.
[12]Schepop H,Jong J,Diest P,et al.Counting of apoptotic cells:a methodological study in invasive breast cancer. J ClinPathol Molpathol,1996,49:214.
[13]王伯纭等编著.病理学技术.人民卫生出版社.2001.
[14]Phil Moffitt. A methyl green-pyronin technique for demonstrating cell death in the murine tumour S180. Biology International,1994,18(6):677-679.
[15]方福德等编著.分子生物学前沿技术.北京医科大学中国协和医科大学联合出版社出版.1998.
[16]Kerr JF, Winterford CM, Harmon BV. Apoptosis. Its significance in cancer and cancer therapy. Cancer,1994,73(8):2013-26.
[17]方成,陈钧辉.细胞凋亡与癌症治疗.中国生化药物杂,2000,21(6)：313-315.
[18]Thompson CB. Apoptosis in the pathogenesis and treatment of diseases. Science,1997:1456-1461
[19]Duke RC, Ojcius DM, Young JD. Cell suicide in health and disease. Scientific American,1996:48-55.
[20]Salomons GS, Brady HJ, Verwijs-Janssen M, et al.The Bax alpha:Bcl-2 ratio modulates the response to dexamethasone in leukaemic cells and is highly variable in childhood acute leukaemia.Int J Cancer.1997,71(6):959-65.
[21]Ando K, Hiroishi K, Kaneko T,et al. Perforin, Fas/Fas ligand, and TNF-alpha pathways as specific and bystander killing mechanisms of hepatitis C virus-specific human CTL.J Immunol,1997,158(11):5283-91.
[22]李杰恩,唐安洲,黄光武,徐志文,周永.鼻咽癌细胞凋亡及凋亡相关基因的表达.中华肿瘤杂志,2000,22(2)：158-160.
[23]Fisher DE.Apoptosis in cancer therapy:crossing the threshold. Cell, 1994:529-542
[24]Hannun YA.Apoptosis and the dilemma of cancer chemotherapy. Blood, 1997:1845-1853
[25]陈绪军综述.肝细胞损伤细胞凋亡及肝细胞保护[J].国外医学外科学分册.2000,27(1)：21.
[26]Brown DG.,Sun XM, Cohen GM.Dexamethasone-induced apoptosis involves cleavage of DNA to large fragments prior to internucleosomal fragmentation. J Biol Chem.1993,268(5):3037-3039.
[27]Herrmannm M, Lorenz HM, Voll R et al. A Rapid and simple method for the isolation of apoptotic DNA fragments. Nucleic Acid Res.1994; 22:5506-5507DNA
[28]郑骏年,谢叔良,陈家存,黄键.流式细胞术定量检测细胞凋亡3种方法的比 较研究.中国免疫学杂志1999,15(10)：467-469.
[29]Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry.J Immunol Methods.1991 Jun 3;139(2):271-9.
[30]Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C.A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V.J Immunol Methods.1995 Jul 17;184(1):39-51.
[31]奥田邦雄,K.G.伊莎克.肝脏肿瘤[M].上海科技出版社,施普林格出版公司,1991.7.
[32]Fadok V A, Voelker D R,Campbell P A et al. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophage. J Immuol,1992;148:2207。
[33]肖恩华.细胞凋亡与肝癌.国外医学临床放射学分册,1999,1：9-12.
[34]肖恩华,胡国栋.化疗栓塞后肝细胞癌细胞凋亡和耐药基因表达的改变.放射学实践,2000,15(6)：387-389.
[35]Xiao E,Li D, Shen S,et al. Effect of preoperative transcatheter arterial chemoembolization on apoptosis of hepatocellular carcinoma cells. Chin Med J (Engl),2003,116(2):203-7.
[36]Harima Y, Harima K, Hasegawa T,et al.Histopathological changes in rabbit uterus carcinoma after transcatheter arterial embolization using cisplatin. Cancer Chemother Pharmacol,1996;38(4):317-22.
[37]肖恩华,胡国栋,刘鹏程,胡道予.化疗栓塞后肝细胞癌细胞凋亡的研究.中华放射学杂志,1999,33(3)：153-155.
[38]Park IC, Park MJ, Hwang CS, et al. Mitomycin C induces apoptosis in a caspases dependent and Fas/CD95 independent manner in human gastricadenocarcinoma cells.Cancer Letters,2000,158:125.
[39]Senaldi G, Shaklee CL, Simon B, Rowan CG, Lacey DL, Hartung T.Keratinocyte growth factor protects murine hepatocytes from tumor necrosis factor-induced apoptosis in vivo and in vitro.Hepatology.1998 Jun;27(6): 1584-91
[1]Goldstein HM, Wallace S, Anderson J H, et al. Transcatheter occlusion of abdominall tumors. Radiology,1976;120 (3):539-545.
[2]黄洁夫,李锦清,梁力建,等.合理运用经导管肝动脉化疗原发性肝癌[J].癌症,1999,18：113-115.
[3]潘群雄,庄建良,曾志雄.经皮肝穿门静脉置管治疗肝癌栓38例分析[J].中国临床医学.2004,11(4)：565-566.
[4]王轩,殷广福,许正昌,等.经肝动脉联合经皮经肝选择性门静脉栓塞化学药的治疗中晚期原发性肝癌65例体会[J].中华普通外科杂志,1999,14(3)：168- 170.
[5]崔林,张志胜,余扬群.肝动脉和门静脉双重化疗栓塞治疗原发性肝癌的临床观察[J].临床肿瘤学杂志,2004,9(4)：404-405.
[6]茅国新,于志坚,张一心.经导管肝动脉和B超引导下经细针门静脉双重化疗栓塞治疗原发性肝癌[J].中华肿瘤杂志.2002,24(4)：391-393.
[7]张积仁.氩氦刀冷冻消融治疗肿瘤[J].中国肿瘤,2007,16(5)：335-337.
[8]Senming Wang, Jiren Zhang, Qiuping Peng. The treatment of irresectable liver tumors by percutaneous trargeted Ar-He cryoablation[J]. International Journal of Mordern Cancer Therapy,2000,3(1):16-18.
[9]王洪武,贺声.经皮穿刺氩氦刀治疗肝癌[J].中国肿瘤临床与康复,2005,12(1)：30-33.
[10]宋谦,李露嘉,夏放,等.CT引导经皮氩氦刀靶向治疗肺癌的临床应用[J].中国肿瘤临床与康复,2005,12(1)：62-64.
[11]石家齐,贾本忠,顾昌世,等.经皮靶向氩氦刀治疗前列腺疾病[J].中华现代外科学杂志,2005,2(3)：210-212.
[12]程颖,张彩霞,秦少波.氩氦刀治疗中晚期肺癌的临床观察[J].吉林医学,2005,26(6)：599-600.
[13]王洪武,贺声,张燕群.经皮穿刺氩氦超导靶向治疗头面部肿瘤[J].中国肿瘤临床与康复,2005,12(3)：251-254.
[14]Jiang HC,Liu LX, Piao DX,et all Clinical short-term results of radiofrequency ablation in liver cancers[J].World J Gastroenterol,2002,8 (4):624-630. [16]
[15]Curely SA. Radiofrequency ablation of malignant liver tumors [J]. Oncologist,2001,6(1):14-23.
[16]Ikeda M, O kada S, U eno H, et al. Radiofrequency ablation and percutaeous ethanol injection in patients with small hepatocellualr carcinoma:a comparative study [J]. Jpn J Clin Oncol,2001,31(7):322-326.
[17]Seki T, Wakabayashi M, Nakagawa T, et al. Percutaneous microwave coagulation therapy for patients with small hepatocellular carcinoma, comparison with percutaneous ethanol injecton therapy [J]. Cancer, 1999,85(8):1694-1702.
[18]Shinna S, Teratani T, Obi S, et al. Nonsurgical treatment of hepatocellular carcinoma:from percutaneous ethanol injection therapy and percutaneous microwave coagulation therapy to radiofrequency ablation [J]. Oncolgy,2002, 62(1):64-68.
[19]王文见,欧阳茂,罗亿治,等.高强度聚焦超声对W256肝癌荷鼠淋巴细胞活性的影响[J].中华实验外科杂志,2001,18(3)：178.
[20]Takegami K, Kaneko Y,Watanabe T, et al. Heating and coagulation volume obtained with high—intensity focused ultrasound therapy:comparison of perflutren protein-type A microspheres and MRX2133 in rabbits[J]. Radiology,2005,237(1):132-136.
[21]Livraghi T. Percutaneous ethanol injection in the treatment of hepatocellular carcinoma in cirrhosis[J]. Hepatogastroenterology,2001,48 (37):20-24.
[22]Ohnishi K, Ohyama N, Ito S,et al. Ultrasound guided intratumor injection of acetic acid for the treatment of small hepatocellar carcinoma[J]. Radiology,1994,193:747-752.
[23]Ohnishi K, Nomura F, Ito S, et al. Prognosis of small hepatocellur carcinoma (less than 3cm) after precutaneous acetic acid injection study of 91 cases[J]. Hepatology,1996,23:994-1002.
[24]Midorikawa T,Kumada K,Kikuchi H,et al.Microwave coagulation therapy for hepatocellular carcinoma [J].J Hepatobiliary Pancreat Surg,2000,7 (3):252-259.
[25]Liang P,Dong BW,Yu X, et al. Prognostic factors for survival in patients with hepatocellular carcinoma after percutaneous microwave ablation[J] Radiology,2005,235(1):299-307.
[26]吴沛宏.肿瘤微创治疗展望.介入放射学杂志,2005,14(6)：561-562.
[27]张智坚,吴孟超,陈汉,等.经皮肝穿刺射频热凝与肝动脉化疗栓塞联合治疗肝细胞癌.中华外科杂志,2002,40：826-829.
[28]吴孟超,程树群.肝癌微创外科治疗的现状和展望.中国微创外科杂志.2005,5(2)：85-87.
[2]汤钊酞主编.肝癌转移复发的基础与临床.上海,上海科技教育出版社.2003：1-51.
[3]汤钊酞.原发性肝癌的研究进展。中国肿瘤临床,1998,25(2)：137-141.
[4]吴孟超.原发性肝癌治疗的进展及展望.第二军医大学学报,2002,23：1-4.
[5]张积仁.Cryocare氩氦靶向肿瘤治疗技术.生物医学工程研究,2005,24(2)：28-32
[6]张积仁.氩氮刀冷冻消融治疗肿瘤[J].中国肿瘤,2007,16(5)：335-337.
[7]吴孟超,陈汉,沈锋,等.微创在肝癌外科治疗中的地位.中国微创外科杂志,2002,2：69-70.
[8]Lau WY, Leung TW, Yu SC, et al. Percutaneous local ablativetherapy for hepatocellular carcinoma:a review and look into the future. Ann Surg,2003, 237:171-179.
[9]Goldstein HM, Wallace S, Anderson J H, et al. Transcatheter occlusion of abdominall tumors. Radiology,1976;120 (3):539-545.
[10]陈勇.一种新的消融剂—碘油化疗药乳剂的临床应用研究.南方医科大学,博士学位论文,2007.
[11]Lin SM, Lin CJ, Lin CC, et al. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less.Gut,2005,54:1151-1156.
[12]陈敏华,严昆,杨薇,等.343例肝恶性肿瘤射频消融疗效及并发症.北京大学学报(医学版)2005,37(3)：292-296.
[13]Ja Kyung Kim, Kwang-Hyub Han, Jong Tae Lee, et al. Long-term Clinical Outcome of Phase Ⅱb Clinical Trial of Percutaneous Injection with Holmium-166/Chitosan Complex (Milican) for the Treatment of Small Hepatocellular Carcinoma. Clinical Cancer Research,2006,12 (2):543-548.
[14]颜红兵,郑广生,吴铁墉.原发性肝癌的经皮酒精注射治疗.中国临床医生,2001,29(4)：24-25.
[15]林红军,张峰.超声引导下无水酒精注射治疗肝癌80例分析.南京医科大学学报(自然科学版),2002,22(6)：521-522.
[16]Fartoux L, Arrive L, Andreani T, et al. Treatment of small hepatocellular carcinoma with acetic acid percutaneous injection. Gastroenterol Clin Biol, 2005,29 (12):1213-1219.
[17]牛俊波.恶性实体肿瘤间质治疗进展.外科理论与实践,2008,13(1)：82-84.
[18]陈翼.原发性肝癌瘤内注射治疗进展.重庆医学,2005,34(11)：1734-1736.
[19]毛军杰.经皮瘤内药物注射治疗肝癌.放射学实践,2008,23(2)：221-223.
[20]Sugiura N. Percutaneous int ratumoral injection of ethanolunder ultrasound imaging for treatment of small hepatocellular carcinoma[J]. Aata Hepatol J PN,1983,30:43.
[21]Livraghi T,Bolondi L. No treatment, resection and ethanol in hepatatocellular carcinoma [J]. J Hepatol,1995,22:522.
[22]Kanaka K,Nakamura,Nuimata K, et al. The long term efficacy of combined transcatheter arterial embolization and percutaneous ethanol injection in the treatment of patient with large hepatocellular carcinoma and cirrhosis[J]. Cancer,1998,82:78
[23]Ohnishi K,Ohyama N, Ito S,et al. Small hepatocellular carcinoma:treatment with US-guided intratumoral injection of acetic[J]. Radiology,1994,193:747
[24]Ohnishi K, Yoshika H, Ito S,et al. Prospective randomised controlled trial comparing percutaneous acetic acid injection and percutaneous ethanol injection for small hapatocellular carcinoma[J]. Hepatology,1998,27:67
[25]黄雯霞.肝内注射华蟾素之治疗肝癌18例初步观察[J].癌症,1990,9(3)：239
[26]冯晓灵,蒋亚生,李柏.肝癌局部注射丝裂霉素与中药肝复康的临床及实验对照分析[J].肿瘤,1994,14：291
[27]杨敏一,梁宝英,余清平,等.B超导向瘤体中心注射去甲基斑蝥素治疗中晚期肝癌41例[J].人民军医,1993,6(9)：44
[28]李浩,祖茂衡.超液化碘油瘤内注射对肝癌细胞作用的实验研究.中国介入影像与治疗学2007,4(5)：383-387.
[29]李华,潘承恩,刘清光,等.Bcl-2, C-myc在肝细胞癌中的表达及临床意义[J].西安医科大学学报,2000；21(2)：152-155.
[30]赵爱志,窦科峰,李开宗,等.肝细胞肝癌中血管内皮生长因子及nm232H1蛋白的表达[J].第四军医大学学报,2000；21(11)：1336-1337.
[31]贾宗良,白建华,王清丽.甲状腺癌患者血清中SIL 22R测定的临床意义 [J].西安医科大学学报,2000；21(2)：164-165.
[32]马列婷,王亚文,李影,等.肝细胞肝癌患者介入治疗后免疫功能的改变.第四军医大学学报,2002；23(8)：3201.
[33]曹驰,李青,梁颖,等.原发性肝癌介入治疗后机体免疫功能的研究.中国医师杂志2005,7(7)：903-905.
[34]Yasutomo K. The cellular and molecularmechanism of CD4/CD8 lineage commitment [J]. J Med Invest,2002,49 (1-2):1-6.
[35]赵志伦,刘永雄,宋子信.肝癌病人化疗栓塞前后LAK细胞活性变化的研究[J].中国肿瘤临床,1996,23(1)：27-30.
[36]曹驰,李彩霞.原发性肝癌的免疫状态与预后的相关性分析[J].肿瘤防治杂志,2004,38(2)：127-130.
[37]陈伟强,张世能.肝癌患者治疗前后T细胞亚群和sIL-2R水平的变化[J].上海免疫学杂志,1998,18(4)：238-240.
[38]Akizuki S, Magara T, Tanaka T. Diminution of the number of gamma delta T lymphocytes in hepatocellular carcinoma patients treated with transcatheter arterialembolization[J]. Nihon-Kinsho-Meneki-Gakkaikaishi,1998,21(3) 108-117.
[39]尹燕明,秦庆亮,张伟等.肝细胞癌热休克蛋白70过表达与自发性癌细胞凋亡[J].中华肝脏病杂志,2001,9(2)：84.
[40]Hino N, Higashit, Nouso K,et al.Apoptosis and proliferation of human hepatocellular carcinoma[J].Liver,1996,16:123.
[41]王冠军,李薇,续哲莉..原发性肝细胞癌细胞凋亡的研究[J].吉林医学,1 999,20(4)：195.
[42]陈胜利.人肝细胞癌细胞凋亡.现代临床医学生物工程学杂志,2002,8(6)：459-462.
[43]肖恩华.细胞凋亡与肝癌.国外医学临床放射学分册,1999,1：9-12.
[44]肖恩华,胡国栋.化疗栓塞后肝细胞癌细胞凋亡和耐药基因表达的改变.放射学实践,2000,1 5(6)：387-389.
[45]吴沛宏.肿瘤微创治疗展望.介入放射学杂志,2005,14(6)：561-562.
[46]张智坚,吴孟超,陈汉,等.经皮肝穿刺射频热凝与肝动脉化疗栓塞联合治疗肝细胞癌.中华外科杂志,2002,40：826-829.
[47]Rossi S, Garbagnati F,Lencioni R, et al. Percutaneous radiofrequency thermal ablation of nonresectable hepatocellular carcinoma after occlusion of tumor blood supply. Radiology,2000,217:119-126.
[48]Lu DS, Raman SS, Limanond P, et al. Influence of large peritumoral vessels on outcome of radiofrequency ablation of liver tumors. J Vas Interv Radiol, 2003,14:1267-1274.
[49]蒋小良,牟培源,李永忠.碘油治疗肝癌的研究进展.现代肿瘤医学,2006,14(1)112-113.
[50]Livraghi T. Percutaneous ethanol injection in the treatment of hepatocellular carcinoma in cirrhosis [J]. Hepatogastroenterology,2001,48:20.
[51]Yoon HK,Song H Y,Sung KB,et al. Percutaneous hot saline injection therapy:effectiveness in large hepatocellular carcinoma[J]. J Vasc Interv Radiol,1999,10:477.
[52]Huang J F, Kuang M,Lu M, et al. Percutaneous hyperthermal distilled water injection therapy (PHDT) for liver cancer [J]. Asian J Surg,1999,22:337.
[53]Gerolami R, Cardoso J,Lewin M, et al. Evalution of HSV2tk gene therapy in a rat model of chemically induced hepatocellular carcinoma by int ratumoral and intrahepatic artery routes[J]. Cancer Res,2000,60:993.
[54]Seol J G,Heo DS,Kim HK,et al. Selective gene expression in hepatic tumor with t rans2arterial delivery of DNA/liposome/transferring complex [J]. In Vivo,2000,14:513.
[55]陈喆.去甲基斑蝥素2泊洛沙姆407缓释剂和无水乙醇的肝癌瘤内注射疗效比较[J].第二军医大学学报,2001,22(7)：606.
[56]戚晓军,赵海东,高文斌,等.三氧化二砷瘤内注射联合肝动脉化疗栓塞治疗肝癌[J].肿瘤学杂志,2003,9(3)：147.
[57]林礼务,何以敉,高上达,等.复方中药经皮瘤内注射诱导肝细胞癌凋亡[J]中国医学影像技术,2002,18(1)：6.
[58]孙铭,朱争艳,方淑昌,等.中药硇砂提取液裸小鼠肿瘤内注射治疗肝癌的实验研究[J].肿瘤防治研究,2002,29(5)：365.
[59]王建平,侯鲁强,刘军伟.肝癌碘油栓塞后碘油沉积量与疗效的相关性.实用医药杂志,2008,25(3)：308.
[1]陈尉峰,主编.医学免疫学[M]。第3版.北京：人民卫生出版社,2002.230-234.
[2]杨镇.肿瘤免疫学[M].第一版,武汉：湖北科学技术出版社,1998：31-45.
[3]余传霖,叶天星,陆德源,等主编.上海：上海医科大学出版社,.现代医学免疫,1997：1022.
[4]Kuss I, Hathaway B, Ferris RL, et, al. Decreased absolute counts of T lymphocyte subsets and their relation to disease in squamous cell carcinoma of the head and neck [J]. Clin CancerRes,2004,10 (11):3755-3762.
[5]Hang K, Hayashi R, Blond—Walker A, et al.The central role of CD4+T cells in the antitumor immune response[J].J Exp Med,1998,188(12): 2357-2368.
[6]李国玲,林华笙,韩雪飞,等.恶性肿瘤患者的免疫学变化[J].中华临床新医学,2004,4(1)：9-10.
[7]乌玉辉,申正堂,海健,等.乳腺癌患者细胞免疫功能的检测[J].中国医师杂志,2001,3(8)：627-628.
[8]刘莉,丁乾,曹如波,等.恶性肿瘤患者外周血CD4+CD25+调节T细胞的检测及其临床意义.临床肿瘤学杂志2005,10(4)：342-345.
[9]龚非力,主编.医学免疫学[M].第2版.北京：科学出版社,2005：390-399.
[10]杨辉.肺癌患者免疫状态的综合评价及化疗对其免疫状态的影响.军事科学医学院,硕士学位论文,2003.
[11]Ormandy LA, Hillemann T, Wedemeyer H, et al. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma[J].Cancer Res,2005,65 (6):2457-2464.
[12]Kamohara Y, Kanematsu T. Treatment of liver cancer:current status and future prospectives [J]. Gan to Kagaku Kyoho,2000,27(7):987-992.
[13]巴德年主编.当代免疫学技术与应用.北京医科大学中国协和医科大学联合出版社.1998：8-12.
[14]陈复兴,刘军权,周忠海,等.癌症患者T细胞亚群的临床意义[J].细胞与分子免疫学杂志,2002,18(1)：55.
[15]周信达.肝癌诊治的若干进展及展望[J].中华消化杂志,1999,19(1)：5-7.
[16]牛俊波.恶性实体肿瘤间质治疗进展.外科理论与实践,2008,13(1)：82-84.
[17]陈翼.原发性肝癌瘤内注射治疗进展.重庆医学,2005,34(11)：1734-1736.
[18]毛军杰.经皮瘤内药物注射治疗肝癌.放射学实践,2008,23(2)：221-223.
[19]Akizuki S, Magara T, Tanaka T. Diminution of the number of gamma delta T lymphocytes in hepatocellular carcinoma patients treated with transcatheter arterial embolization [J]. Nihon-Kinsho-Meneki-Gakkaikaishi,1998, 21(3):108-117
[20]韩秀婕,董宝玮,梁萍,等.微波治疗肝癌后局部细胞免疫变化及其对临床疗效影响.中国癌症杂志,2007,17(2)：135-138.
[21]Doherty DG, Ofarrelly C. Innate and adaptive lymphoid cells in the human liver[J]. Immunol Rev,2000,174 (4):5-20.
[22]Seki S, Habu Y, Kawamura T, et al. The liver as a crucial organ in the first line of host defense [J]. Immunol Rev,2000,174 (4):35-46.
[23]Cole WH, Humphrey L. Need for immunologic stimulators during immunosupp ression produced by major cancer surgery[J]. Ann Surg,1985,202 (1):9220.
[24]Litton MJ, Dohlsten M, Rosendahl A, et al. The distinct role of CD4+ and CD8+T cell during the antitumor effects of targeted superantigens[J]. Br J Cancer,1999,81 (2):359-366.
[25]张志培,施新猷,李六金,等.接种9724肿瘤细胞后不同免疫力小鼠体内T细胞的作用[J].中国肿瘤生物治疗杂志,2001,8(2)：1182121.
[26]牟培源,董宝玮,梁萍,等.超声引导高聚生瘤区注射在肝癌介入治疗中的临床应用评价.中国肿瘤临床,2002,29(11)：797-798,801.
[1]Kerr JF,Wyllie AH,Currie AR.Apoptosis:a basic biological phenomenon with wide-ranging implication in tissue Kinetics.Br J Cancer,1972,26(4):239-257.
[2]Thompson CB.Apoptosis in the pathogenesis and treatment of disease. Science,1995,267(5203):1456-62.
[3]Evan G,Littlewood T.A matter of life and cell death. Science,1998,281: 1317-1321.
[4]张学军,郭礼和.细胞凋亡失调与疾病的关系研究.中华医学杂志,1998,78(8)：565-566.
[5]尹燕明,秦庆亮,张伟等.肝细胞癌热休克蛋白70过表达与自发性癌细胞凋亡[J].中华肝脏病杂志,2001,9(2)：84
[6]Hino N,Higashi t,Nouso K, et al. A poptosis and proliferation of human hepatocellular carcinoma[J].Liver,1996,16:123
[7]王冠军,李薇,续哲莉.原发性肝细胞癌细胞凋亡的研究[J].吉林医学,1999,20(4)：195
[8]陈胜利,张静.人肝细胞癌细胞凋亡[J].现代临床医学生物工程学杂,2002,8(6)459-462
[9]Akins PT,Liu PK, Hsu CY,et al. Immediate early gene expression in response to cerebral ischemia. friend or foe? Stroke,1996,27:1682-1687.
[10]An WG, Kanekal M, Simon MC, et al. Stabilization of wild2type p53 byhypoxia-inducile factor 1α. Nature,1998,392:405-408.
[11]陈胜利,徐兆栋.兔VX2肝癌模型与实验性肝癌介入治疗.现代临床医学生物工程学杂志.2003,9(4)：371-373.
[12]Schepop H,Jong J,Diest P,et al.Counting of apoptotic cells:a methodological study in invasive breast cancer. J ClinPathol Molpathol,1996,49:214.
[13]王伯纭等编著.病理学技术.人民卫生出版社.2001.
[14]Phil Moffitt. A methyl green-pyronin technique for demonstrating cell death in the murine tumour S180. Biology International,1994,18(6):677-679.
[15]方福德等编著.分子生物学前沿技术.北京医科大学中国协和医科大学联合出版社出版.1998.
[16]Kerr JF, Winterford CM, Harmon BV. Apoptosis. Its significance in cancer and cancer therapy. Cancer,1994,73(8):2013-26.
[17]方成,陈钧辉.细胞凋亡与癌症治疗.中国生化药物杂,2000,21(6)：313-315.
[18]Thompson CB. Apoptosis in the pathogenesis and treatment of diseases. Science,1997:1456-1461
[19]Duke RC, Ojcius DM, Young JD. Cell suicide in health and disease. Scientific American,1996:48-55.
[20]Salomons GS, Brady HJ, Verwijs-Janssen M, et al.The Bax alpha:Bcl-2 ratio modulates the response to dexamethasone in leukaemic cells and is highly variable in childhood acute leukaemia.Int J Cancer.1997,71(6):959-65.
[21]Ando K, Hiroishi K, Kaneko T,et al. Perforin, Fas/Fas ligand, and TNF-alpha pathways as specific and bystander killing mechanisms of hepatitis C virus-specific human CTL.J Immunol,1997,158(11):5283-91.
[22]李杰恩,唐安洲,黄光武,徐志文,周永.鼻咽癌细胞凋亡及凋亡相关基因的表达.中华肿瘤杂志,2000,22(2)：158-160.
[23]Fisher DE.Apoptosis in cancer therapy:crossing the threshold. Cell, 1994:529-542
[24]Hannun YA.Apoptosis and the dilemma of cancer chemotherapy. Blood, 1997:1845-1853
[25]陈绪军综述.肝细胞损伤细胞凋亡及肝细胞保护[J].国外医学外科学分册.2000,27(1)：21.
[26]Brown DG.,Sun XM, Cohen GM.Dexamethasone-induced apoptosis involves cleavage of DNA to large fragments prior to internucleosomal fragmentation. J Biol Chem.1993,268(5):3037-3039.
[27]Herrmannm M, Lorenz HM, Voll R et al. A Rapid and simple method for the isolation of apoptotic DNA fragments. Nucleic Acid Res.1994; 22:5506-5507DNA
[28]郑骏年,谢叔良,陈家存,黄键.流式细胞术定量检测细胞凋亡3种方法的比 较研究.中国免疫学杂志1999,15(10)：467-469.
[29]Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry.J Immunol Methods.1991 Jun 3;139(2):271-9.
[30]Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C.A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V.J Immunol Methods.1995 Jul 17;184(1):39-51.
[31]奥田邦雄,K.G.伊莎克.肝脏肿瘤[M].上海科技出版社,施普林格出版公司,1991.7.
[32]Fadok V A, Voelker D R,Campbell P A et al. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophage. J Immuol,1992;148:2207。
[33]肖恩华.细胞凋亡与肝癌.国外医学临床放射学分册,1999,1：9-12.
[34]肖恩华,胡国栋.化疗栓塞后肝细胞癌细胞凋亡和耐药基因表达的改变.放射学实践,2000,15(6)：387-389.
[35]Xiao E,Li D, Shen S,et al. Effect of preoperative transcatheter arterial chemoembolization on apoptosis of hepatocellular carcinoma cells. Chin Med J (Engl),2003,116(2):203-7.
[36]Harima Y, Harima K, Hasegawa T,et al.Histopathological changes in rabbit uterus carcinoma after transcatheter arterial embolization using cisplatin. Cancer Chemother Pharmacol,1996;38(4):317-22.
[37]肖恩华,胡国栋,刘鹏程,胡道予.化疗栓塞后肝细胞癌细胞凋亡的研究.中华放射学杂志,1999,33(3)：153-155.
[38]Park IC, Park MJ, Hwang CS, et al. Mitomycin C induces apoptosis in a caspases dependent and Fas/CD95 independent manner in human gastricadenocarcinoma cells.Cancer Letters,2000,158:125.
[39]Senaldi G, Shaklee CL, Simon B, Rowan CG, Lacey DL, Hartung T.Keratinocyte growth factor protects murine hepatocytes from tumor necrosis factor-induced apoptosis in vivo and in vitro.Hepatology.1998 Jun;27(6): 1584-91
[1]Goldstein HM, Wallace S, Anderson J H, et al. Transcatheter occlusion of abdominall tumors. Radiology,1976;120 (3):539-545.
[2]黄洁夫,李锦清,梁力建,等.合理运用经导管肝动脉化疗原发性肝癌[J].癌症,1999,18：113-115.
[3]潘群雄,庄建良,曾志雄.经皮肝穿门静脉置管治疗肝癌栓38例分析[J].中国临床医学.2004,11(4)：565-566.
[4]王轩,殷广福,许正昌,等.经肝动脉联合经皮经肝选择性门静脉栓塞化学药的治疗中晚期原发性肝癌65例体会[J].中华普通外科杂志,1999,14(3)：168- 170.
[5]崔林,张志胜,余扬群.肝动脉和门静脉双重化疗栓塞治疗原发性肝癌的临床观察[J].临床肿瘤学杂志,2004,9(4)：404-405.
[6]茅国新,于志坚,张一心.经导管肝动脉和B超引导下经细针门静脉双重化疗栓塞治疗原发性肝癌[J].中华肿瘤杂志.2002,24(4)：391-393.
[7]张积仁.氩氦刀冷冻消融治疗肿瘤[J].中国肿瘤,2007,16(5)：335-337.
[8]Senming Wang, Jiren Zhang, Qiuping Peng. The treatment of irresectable liver tumors by percutaneous trargeted Ar-He cryoablation[J]. International Journal of Mordern Cancer Therapy,2000,3(1):16-18.
[9]王洪武,贺声.经皮穿刺氩氦刀治疗肝癌[J].中国肿瘤临床与康复,2005,12(1)：30-33.
[10]宋谦,李露嘉,夏放,等.CT引导经皮氩氦刀靶向治疗肺癌的临床应用[J].中国肿瘤临床与康复,2005,12(1)：62-64.
[11]石家齐,贾本忠,顾昌世,等.经皮靶向氩氦刀治疗前列腺疾病[J].中华现代外科学杂志,2005,2(3)：210-212.
[12]程颖,张彩霞,秦少波.氩氦刀治疗中晚期肺癌的临床观察[J].吉林医学,2005,26(6)：599-600.
[13]王洪武,贺声,张燕群.经皮穿刺氩氦超导靶向治疗头面部肿瘤[J].中国肿瘤临床与康复,2005,12(3)：251-254.
[14]Jiang HC,Liu LX, Piao DX,et all Clinical short-term results of radiofrequency ablation in liver cancers[J].World J Gastroenterol,2002,8 (4):624-630. [16]
[15]Curely SA. Radiofrequency ablation of malignant liver tumors [J]. Oncologist,2001,6(1):14-23.
[16]Ikeda M, O kada S, U eno H, et al. Radiofrequency ablation and percutaeous ethanol injection in patients with small hepatocellualr carcinoma:a comparative study [J]. Jpn J Clin Oncol,2001,31(7):322-326.
[17]Seki T, Wakabayashi M, Nakagawa T, et al. Percutaneous microwave coagulation therapy for patients with small hepatocellular carcinoma, comparison with percutaneous ethanol injecton therapy [J]. Cancer, 1999,85(8):1694-1702.
[18]Shinna S, Teratani T, Obi S, et al. Nonsurgical treatment of hepatocellular carcinoma:from percutaneous ethanol injection therapy and percutaneous microwave coagulation therapy to radiofrequency ablation [J]. Oncolgy,2002, 62(1):64-68.
[19]王文见,欧阳茂,罗亿治,等.高强度聚焦超声对W256肝癌荷鼠淋巴细胞活性的影响[J].中华实验外科杂志,2001,18(3)：178.
[20]Takegami K, Kaneko Y,Watanabe T, et al. Heating and coagulation volume obtained with high—intensity focused ultrasound therapy:comparison of perflutren protein-type A microspheres and MRX2133 in rabbits[J]. Radiology,2005,237(1):132-136.
[21]Livraghi T. Percutaneous ethanol injection in the treatment of hepatocellular carcinoma in cirrhosis[J]. Hepatogastroenterology,2001,48 (37):20-24.
[22]Ohnishi K, Ohyama N, Ito S,et al. Ultrasound guided intratumor injection of acetic acid for the treatment of small hepatocellar carcinoma[J]. Radiology,1994,193:747-752.
[23]Ohnishi K, Nomura F, Ito S, et al. Prognosis of small hepatocellur carcinoma (less than 3cm) after precutaneous acetic acid injection study of 91 cases[J]. Hepatology,1996,23:994-1002.
[24]Midorikawa T,Kumada K,Kikuchi H,et al.Microwave coagulation therapy for hepatocellular carcinoma [J].J Hepatobiliary Pancreat Surg,2000,7 (3):252-259.
[25]Liang P,Dong BW,Yu X, et al. Prognostic factors for survival in patients with hepatocellular carcinoma after percutaneous microwave ablation[J] Radiology,2005,235(1):299-307.
[26]吴沛宏.肿瘤微创治疗展望.介入放射学杂志,2005,14(6)：561-562.
[27]张智坚,吴孟超,陈汉,等.经皮肝穿刺射频热凝与肝动脉化疗栓塞联合治疗肝细胞癌.中华外科杂志,2002,40：826-829.
[28]吴孟超,程树群.肝癌微创外科治疗的现状和展望.中国微创外科杂志.2005,5(2)：85-87.